📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. (2020)

First Author: Hanrahan JP

Attributed to: Physical activity epidemiology funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s00125-019-05062-x

PubMed Identifier: 31858186

Publication URI: http://europepmc.org/abstract/MED/31858186

Type: Journal Article/Review

Volume: 63

Parent Publication: Diabetologia

Issue: 4

ISSN: 0012-186X